Expression of transmembrane adaptor protein PAG/Cbp in diffuse large B-cell lymphoma: Immunohistochemical study of 73 cases

2007 ◽  
Vol 203 (4) ◽  
pp. 193-198 ◽  
Author(s):  
Alexandr Svec
Keyword(s):  
B Cell ◽  
Immunohistochemical Study ◽  
Cell Lymphoma ◽  
Adaptor Protein ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals A case of diagnosis of diffuse large b-cell lymphoma with extranodular cervical disease

2021 ◽  
pp. 84-90
Author(s):  
A. A. Grigorenko ◽  
V. V. Voytsekhovskiy ◽  
S. N. Roshchin
Keyword(s):  
T Lymphocytes ◽  
B Cell ◽  
Tumor Cells ◽  
Immunohistochemical Study ◽  
Cell Lymphoma ◽  
Malignant Neoplasm ◽  
B Cell Lymphoma ◽  
The Body ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Aim. Demonstration of a case of diagnosing extranodal diffuse large B-cell lymphoma of rare localization – with a massive lesion of the cervix with spread to the body of the uterus and the anterior wall of the vagina.Results. The patient, born in 1991, considers herself ill since December 2020, when watery, bloody discharge from the genital tract first appeared. She went to the gynecologist at the place of residence; upon examination, a malignant neoplasm was suspected. For further examination and treatment, she was sent to the Amur Regional Oncological Dispensary, where a morphological and immunohistochemical study of the biopsy material was performed. In a histological specimen, there is a picture of lymphoma. Immunohistochemical study: tumor cells express CD10, CD20, BCL6, CD23. Tumor cells do not express CD5 (+ on small T-lymphocytes), BCL2 (+ on small T-lymphocytes), CD30, C-MYC, MUM1. When reacting with Ki-67, 90% of tumor cells are positive. The morphoimmunohistochemical picture is characteristic of diffuse large Bcell lymphoma from cells of germ cell centers.Conclusion. Diagnosis of extranodal lymphoma can be very difficult, and the leading role belongs to an experienced morphologist and the availability of modern diagnostics of the variant of lymphoma. 

Can Cutaneous Low-Grade B-cell Lymphoma Transform Into Primary Cutaneous Diffuse Large B-cell Lymphoma? An Immunohistochemical Study of 82 cases

2014 ◽  
Vol 36 (6) ◽  
pp. 478-482 ◽  
Author(s):  
Jose A. Plaza ◽  
Denisa Kacerovska ◽  
Martin Sangueza ◽  
Stefan Schieke ◽  
Noelle Buonaccorsi ◽  
...  
Keyword(s):  
B Cell ◽  
Immunohistochemical Study ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Haematologica ◽  
2020 ◽  
pp. 0-0
Author(s):  
Youssef Youssef ◽  
Vrajesh Karkhanis ◽  
Wing Keung Chan ◽  
Frankie Jeney ◽  
Alessandro Canella ◽  
...  
Keyword(s):  
B Cell ◽  
Large Scale ◽  
Cell Lymphoma ◽  
Molecular Subtype ◽  
Regulatory Protein ◽  
Adaptor Protein ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Novel Therapeutic

Diffuse large B-cell lymphoma (DLBCL) is the most common Non-Hodgkin’s lymphoma and is characterized by a remarkable heterogeneity with diverse variants that can be identified histologically and molecularly. Large-scale gene expression profiling studies have identified the germinal center B-cell (GCB-) and activated B-cell (ABC-) subtypes. Standard chemo-immunotherapy remains standard front line therapy, curing approximately two thirds of patients. Patients with refractory disease or those who relapse after salvage treatment have an overall poor prognosis highlighting the need for novel therapeutic strategies. Transducin β-like protein 1 (TBL1) is an exchange adaptor protein encoded by the TBL1X gene and known to function as a master regulator of the Wnt signalling pathway by binding to β-CATENIN and promoting its downstream transcriptional program. Here, we show that, unlike normal B-cells, DLBCL cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome regardless of DLBCL molecular subtype. Genetic deletion of TBL1 and pharmacological approach using tegavivint, a first-in-class small molecule targeting TBL1 (Iterion Therapeutics), promotes DLBCL cell death in vitro and in vivo. Through an integrated genomic, biochemical, and pharmacologic analyses, we characterized a novel, β-CATENIN independent, post-transcriptional oncogenic function of TBL1 in DLBCL where TBL1 modulates the stability of key oncogenic proteins such as PLK1, MYC, and the autophagy regulatory protein BECLIN-1 through its interaction with a SKP1-CUL1-F-box (SCF) protein supercomplex. Collectively, our data provide the rationale for targeting TBL1 as a novel therapeutic strategy in DLBCL.

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document